Overview

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin